Sagimet Biosciences Inc.

The current price of SGMT is $9.12 — it has decreased by 8.71% since the previous close. Data as of Nov 5, 2026.

SGMT is down 12.39% over the past week, up 1.00% over the past month and up 17.37% over the past year. The price is above its 200-day moving average of $7.55.

Analysts' average 12-month price target for SGMT is $20.00, which implies 119.30% upside from the current price. Individual estimates range from $7.00 to $29.00.

Of the 12 analysts covering Sagimet Biosciences Inc., 2 rate it a strong buy, 9 rate it a buy and 1 rates it a sell. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.

Sagimet Biosciences Inc. has a market capitalization of $297.15M. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.

In its most recent quarterly report, Sagimet Biosciences Inc. posted a loss of $0.26 per share against an estimate of -$0.251, missing expectations by 3.59%. Upcoming reports are listed in the earnings calendar.

Sagimet Biosciences Inc. has not paid any dividends over the past year.

Companies most comparable to Sagimet Biosciences Inc. include Achieve Life Sciences, Inc., Assembly Biosciences, Inc., Zura Bio Limited, Atea Pharmaceuticals, Inc. and Arcturus Therapeutics Holdings Inc.

In the latest trading session SGMT moved between $9.06 and $9.95, a range of 9.81% of its current price.

Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Sagimet Biosciences Inc. shows a sell rating today and a buy rating on the weekly timeframe. Market conditions change quickly, so it is worth looking further ahead as well — the 1-month rating for Sagimet Biosciences Inc. is buy. Technical ratings are indicators, not investment advice.

Over the past 52 weeks SGMT has traded between $4.50 and $11.45. The current price is 20.35% below its 52-week high.